In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Durect (DRRX - Research Report), with a price target of $6.00. The company's shares opened today at $0.58.Arce covers the Healthcare sector, focusing on stocks such as Cidara Therapeutics, Assembly Biosciences, and Aurinia Pharmaceuticals. According to TipRanks, Arce has an average return of 3.7% and a 35.14% success rate on recommended stocks. The analyst consensus on Durect is currently a Moderate Buy rating.See the top stocks recommended by analysts >>Based on Durect's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $2.
https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-durect-drrx?utm_source=advfn.com&utm_medium=referral
Durect (NASDAQ:DRRX)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more Durect Charts.
Durect (NASDAQ:DRRX)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more Durect Charts.